Prescription Medicine for Men Over 40: A Complete Clinical Guide

Why Men Over 40 Need a Different Prescription Framework

After 40, the hormonal and metabolic environment shifts in ways that make standard adult dosing and single-condition thinking inadequate. Testosterone falls. Visceral fat accumulates. Blood pressure creeps up. Glucose tolerance worsens. These processes are not independent of each other; they interact and accelerate one another.

A 2019 analysis in the Journal of Clinical Endocrinology and Metabolism found that men with hypogonadism had a 2.4-fold higher prevalence of metabolic syndrome compared with eugonadal men of the same age (JCEM, 2019). That overlap means a prescriber treating one condition frequently should reassess whether adjacent conditions need treatment too.

The Five Core Clinical Domains

The prescription field for men over 40 organizes neatly into five domains:

1. Hormonal optimization (testosterone, DHEA-adjacent therapies)
2. Metabolic and weight management (GLP-1 receptor agonists, metformin)
3. Cardiovascular risk reduction (statins, ACE inhibitors, aspirin)
4. Sexual health (PDE5 inhibitors, penile injection therapy)
5. Androgenic conditions (benign prostatic hyperplasia, male-pattern hair loss)

Each section below covers one domain in depth, with an evidence grade, dosing range, and monitoring checklist.

Testosterone Replacement Therapy (TRT)

Hypogonadism in men is defined by the American Urological Association as a total serum testosterone below 300 ng/dL on two morning samples, combined with at least one symptom (low libido, fatigue, depressed mood, or reduced lean mass). The AUA's 2018 guideline states: "Testosterone therapy is indicated for men with symptomatic hypogonadism confirmed by low serum testosterone levels" (AUA Guideline, 2018).

Available Formulations

| Formulation | Typical Dose | Dosing Frequency | Notes | |---|---|---|---| | Testosterone cypionate (IM) | 100-200 mg | Every 1-2 weeks | Most studied; low cost | | Testosterone enanthate (IM) | 100-200 mg | Every 1-2 weeks | Interchangeable with cypionate | | Testosterone gel 1.62% | 40.5-81 mg | Daily | Risk of transdermal transfer to partners | | Testosterone nasal gel (Natesto) | 11 mg per nostril | Three times daily | Preserves LH/FSH; fertility-friendly | | Subcutaneous pellets (Testopel) | 150-450 mg total | Every 3-6 months | Office procedure; steady levels |

What the Evidence Shows

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials (N=790 men aged 65+), found that TRT significantly improved sexual function, mood, and bone mineral density but showed mixed results on physical performance (NEJM, 2016). Lean mass gains were modest (average 1.6 kg) but statistically significant at 12 months.

A 2023 meta-analysis in JAMA Network Open (44 RCTs, N=6,625) confirmed that TRT reduced fat mass and improved insulin sensitivity in hypogonadal men, with a weighted mean reduction of 1.7 kg in fat mass (JAMA Network Open, 2023).

Monitoring on TRT

Labs at baseline, then at 3 and 6 months, then annually:

• Total and free testosterone (target: 400-700 ng/dL mid-cycle)
• Hematocrit (stop or dose-reduce if above 54%)
• PSA (suspend therapy if PSA rises more than 1.4 ng/mL in 12 months)
• Lipid panel and CBC

Men wishing to preserve fertility should discuss human chorionic gonadotropin (hCG) co-administration or switch to nasal testosterone, since exogenous testosterone suppresses endogenous LH and FSH, leading to testicular atrophy and azoospermia in a significant proportion of users.

GLP-1 Receptor Agonists for Weight and Metabolic Health

Obesity in men over 40 is not merely cosmetic. Visceral adiposity suppresses testosterone through peripheral aromatization of androgens to estrogens, raises cardiovascular risk, and worsens insulin resistance. GLP-1 receptor agonists address several of these simultaneously.

Semaglutide (Ozempic / Wegovy)

In STEP-1 (N=1,961), once-weekly subcutaneous semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo (P<0.001) (NEJM, 2021). Men in subgroup analyses lost roughly equivalent percentages to women but started at higher absolute weights, meaning actual kilogram losses were larger.

The SELECT trial (N=17,604), which enrolled adults with established cardiovascular disease but without diabetes, showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% over a median of 34.2 months (NEJM, 2023). Men over 40 with a prior MI or stroke are now among the clearest candidates.

Tirzepatide (Mounjaro / Zepbound)

Tirzepatide acts on both GLP-1 and GIP receptors. SURMOUNT-1 (N=2,539) showed 20.9% mean weight reduction at the 15 mg dose at 72 weeks (NEJM, 2022). That figure exceeds any previously approved pharmacotherapy for obesity.

For men with type 2 diabetes, the SURPASS-2 trial (N=1,879) compared tirzepatide 15 mg to semaglutide 1 mg and found tirzepatide reduced HbA1c by 2.46% versus 1.86% for semaglutide (P<0.001) (NEJM, 2021).

Dosing and Side Effect Profile

Both agents are titrated slowly to reduce nausea. Semaglutide starts at 0.25 mg weekly for 4 weeks, escalating over 16-20 weeks to the 2.4 mg maintenance dose. Tirzepatide starts at 2.5 mg weekly, escalating every 4 weeks to a maximum of 15 mg. The most common adverse events are gastrointestinal: nausea (44% with semaglutide 2.4 mg in STEP-1), diarrhea, and constipation. Pancreatitis and thyroid C-cell tumors (rodent data only) are labeled warnings; both drugs are contraindicated in men with a personal or family history of medullary thyroid carcinoma.

Cardiovascular Risk Reduction

Cardiovascular disease remains the leading cause of death in American men, accounting for about one in four male deaths annually per CDC mortality data (CDC, 2023).

Statins

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease recommends initiating statin therapy in adults aged 40-75 with LDL-C of 70-189 mg/dL and an estimated 10-year ASCVD risk of 7.5% or higher (ACC/AHA, 2019). The most commonly prescribed options:

• Atorvastatin 10-80 mg daily (high-intensity: 40-80 mg; reduces LDL-C by 38-51%)
• Rosuvastatin 5-40 mg daily (high-intensity: 20-40 mg; reduces LDL-C by 38-53%)
• Pravastatin 40-80 mg daily (moderate-intensity; preferred in men on certain HIV antiretrovirals)

The JUPITER trial (N=17,802) showed rosuvastatin 20 mg reduced first major cardiovascular events by 44% in men with LDL-C below 130 mg/dL but elevated hsCRP (NEJM, 2008).

Antihypertensives

The ACC/AHA 2017 hypertension guideline defines stage 1 hypertension as a systolic of 130-139 mmHg or diastolic of 80-89 mmHg. For men with stage 2 hypertension (systolic at or above 140) or diabetes, first-line choices include:

• ACE inhibitors (lisinopril 10-40 mg daily)
• ARBs (losartan 50-100 mg daily)
• Thiazide diuretics (chlorthalidone 12.5-25 mg daily)
• Calcium channel blockers (amlodipine 5-10 mg daily)

Low-Dose Aspirin

The 2022 USPSTF update recommends against initiating aspirin in adults aged 60 and older for primary prevention, citing evidence that bleeding risk offsets benefit in that group. Men aged 40-59 with a 10-year ASCVD risk of 10% or greater may still benefit, and the decision should be individualized (USPSTF, 2022).

Erectile Dysfunction: PDE5 Inhibitors and Beyond

The Massachusetts Male Aging Study (N=1,290 men aged 40-70) found a combined prevalence of complete, moderate, and minimal erectile dysfunction of 52% (J Urol, 1994). Prevalence rises with age, diabetes, and cardiovascular disease.

First-Line: Oral PDE5 Inhibitors

All four approved PDE5 inhibitors work by blocking the enzyme that breaks down cyclic GMP, maintaining smooth muscle relaxation in the corpus cavernosum. They do not cause erections without sexual stimulation.

| Drug | Onset | Duration | Starting Dose | Key Advantage | |---|---|---|---|---| | Sildenafil (Viagra) | 30-60 min | 4-6 hours | 50 mg | Most clinical data | | Tadalafil (Cialis) | 30-45 min | Up to 36 hours | 10 mg (PRN) or 5 mg daily | Daily option; also treats BPH | | Vardenafil (Levitra) | 30-60 min | 4-5 hours | 10 mg | Modest food interaction advantage | | Avanafil (Stendra) | 15-30 min | 6 hours | 100 mg | Fastest onset |

Tadalafil 5 mg daily is the only PDE5 inhibitor also FDA-approved for lower urinary tract symptoms from BPH, making it a two-for-one option in older men with both conditions.

Second-Line and Combination Options

Men who do not respond to oral PDE5 inhibitors at maximum doses may be candidates for:

• Intraurethral alprostadil (MUSE): 125-1,000 mcg pellet; ~43% response rate in clinical trials (FDA label, alprostadil)
• Intracavernosal injection therapy (Trimix / Bimix): Combination of alprostadil, phentolamine, and papaverine; response rates above 80% in PDE5 non-responders
• Vacuum erection devices (non-prescription, but commonly co-prescribed)
• Penile prosthesis (surgical; reserved for refractory cases)

Testosterone normalization often improves PDE5 inhibitor response in hypogonadal men, which is why evaluating both conditions together is standard practice.

Androgenic Conditions: BPH and Male-Pattern Hair Loss

Benign Prostatic Hyperplasia (BPH)

BPH affects roughly 50% of men in their 50s and up to 90% by age 85 (NIH, NIDDK). Prescription options include:

• Alpha-blockers (tamsulosin 0.4 mg daily): Relax smooth muscle in the prostate and bladder neck; symptom relief within 1-2 weeks but no effect on prostate volume.
• 5-alpha reductase inhibitors (finasteride 5 mg daily or dutasteride 0.5 mg daily): Reduce prostate volume by 20-25% over 6-12 months; most effective in prostates above 40 mL.
• Combination therapy: The MTOPS trial (N=3,047) found that combination doxazosin plus finasteride reduced BPH clinical progression by 67% versus placebo, compared with 34% for doxazosin alone and 30% for finasteride alone (NEJM, 2003).

Male-Pattern Hair Loss (Androgenetic Alopecia)

Finasteride 1 mg daily (Propecia) inhibits type II 5-alpha reductase, reducing scalp and serum DHT by approximately 70%. In the Proscar Long-Term Efficacy and Safety Study (PLESS) data adapted for hair loss, 87% of men on finasteride 1 mg maintained or increased hair count at 2 years versus 42% on placebo (JAAD, 1999).

Minoxidil 5% topical solution or 1 mg oral minoxidil is commonly added as a second agent. Oral minoxidil 2.5 mg daily showed a mean 12.4% increase in hair density at 24 weeks in a 2022 RCT (JAAD, 2022).

Post-finasteride syndrome (persistent sexual side effects after stopping the drug) is reported in a subset of men; current evidence puts the incidence of persistent sexual dysfunction at 1-2% but acknowledges under-reporting.

Metabolic Health: Prediabetes, Insulin Resistance, and Type 2 Diabetes

Metformin

Metformin (500-2,000 mg daily in divided doses) remains first-line for type 2 diabetes per ADA Standards of Care. The Diabetes Prevention Program (N=3,234) showed metformin 850 mg twice daily reduced progression from prediabetes to diabetes by 31% over 2.8 years in adults with elevated fasting glucose (NEJM, 2002). Men with a BMI above 35 and fasting glucose between 100-125 mg/dL are reasonable candidates for off-label metformin under close monitoring.

The American Diabetes Association's 2024 Standards of Care state: "Metformin therapy for prevention of type 2 diabetes should be considered in adults with prediabetes, especially those with BMI <35 kg/m2, those aged <60 years, and women with prior gestational diabetes mellitus" (ADA Standards, 2024).

SGLT2 Inhibitors and GLP-1 Agonists in Diabetes

Men with type 2 diabetes and established ASCVD or high cardiovascular risk benefit from SGLT2 inhibitors (empagliflozin 10-25 mg daily, dapagliflozin 10 mg daily) in addition to metformin. EMPA-REG OUTCOME (N=7,020) showed empagliflozin reduced cardiovascular death by 38% versus placebo in this population (NEJM, 2015).

Who Should Not Use These Medications

Every drug class above carries absolute or relative contraindications that are especially relevant in men over 40:

• TRT: Active prostate cancer, untreated severe BPH with urinary retention, hematocrit above 54%, or unstable heart failure
• PDE5 inhibitors: Concurrent use of nitrates in any form (sublingual, patch, or spray); co-administration can cause severe hypotension
• GLP-1 agonists: Personal or family history of medullary thyroid carcinoma or MEN-2 syndrome
• Statins: Active liver disease or unexplained persistent elevated transaminases; caution with grapefruit consumption on some formulations
• Finasteride: Not for use by men planning conception in the near term; drug excreted in semen and associated with sperm DNA fragmentation in some studies

How to Prioritize: A Decision Framework for Men Over 40

The sequence below guides clinical priority when multiple conditions are present simultaneously.

Step 1, Screen first. Order a morning fasting panel: total testosterone (before 10 AM), lipid panel, fasting glucose, HbA1c, PSA, CBC, and comprehensive metabolic panel. Add an ASCVD 10-year risk calculation.

Step 2, Address cardiovascular risk. If 10-year ASCVD risk is 7.5% or higher and LDL is above 70, initiate a statin. Blood pressure at or above 130/80 warrants at minimum lifestyle counseling and, at or above 140/90, pharmacotherapy.

Step 3, Address metabolic disease. If HbA1c is 5.7-6.4%, consider metformin off-label plus GLP-1 if BMI is above 27. If HbA1c is 6.5% or higher, formal diabetes management is required.

Step 4, Address hormonal deficiency. If total testosterone is below 300 ng/dL on two morning draws and symptoms are present, TRT is appropriate. Choose formulation based on fertility intent, lifestyle, and adherence preference.

Step 5, Address sexual function. Once cardiovascular and hormonal status is optimized, trial a PDE5 inhibitor. Start with sildenafil 50 mg or tadalafil 5 mg daily. Escalate or switch agents after 4-6 attempts at each dose.

Step 6, Address androgenic conditions. If BPH symptoms are present (IPSS score above 7), add tamsulosin first. If hair loss is a concern, finasteride 1 mg plus topical minoxidil 5% is a well-studied combination.

Monitoring Schedule Summary

| Medication Class | Baseline Labs | 3-Month Check | 6-Month Check | Annual | |---|---|---|---|---| | TRT | Total T, hematocrit, PSA, LFTs | Total T, hematocrit | Full panel | Full panel + DRE | | GLP-1 agonists | HbA1c, lipids, renal function | Weight, GI symptoms | HbA1c, weight | Full metabolic panel | | Statins | LFTs, CK, lipids | Repeat lipids only if dose changed | Lipids | Lipids, LFTs | | PDE5 inhibitors | BP, ECG if cardiac history | PRN if side effects | PRN | Annual BP | | Metformin | Renal function (eGFR), B12 | eGFR if borderline | B12 if symptomatic | eGFR, B12 | | Finasteride 1 mg | PSA baseline | PSA at 6 months (establish new baseline) | Symptom review | PSA annually |